Clinical Trial Update: Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Hypo-Combi Trial evaluating hypofractionated EBRT plus HDR-BT boost in prostate cancer, currently phase 1/2 and not actively recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Radiation Toxicity

Snippet

Sponsor: German Oncology Center, Cyprus | Conditions: Prostate Adenocarcinoma, Radiation Toxicity | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING